Akebia Therapeutics

Akebia Therapeutics

A company developing Hypoxia Inducible Factor therapies to treat kidney diseases and other conditions

Akebia Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts that was founded in 2007 by Joseph Gardner. The company is focused on the development and commercialization of therapeutics for patients with chronic kidney disease.

The company's lead product candidate is Vadadustat, a hypoxia inducible factor (HIF) stabilizer that inhibits the prolyl hydrolase (PH) enzyme. It is in Phase 3 of clinical development for patients with renal anemia. Vadadustat is designed to mimic the body's adaptive response to hypoxia, such as that experienced at moderate altitude. The drug is currently an investigational drug and has not yet been approved by the US FDA or any other regulatory authority.

Akebia is developing other HIF-based portfolio of product candidates that target serious diseases of high unmet need. This includes those developed internally as well as in-licensed products.

Merger

In December 2018, Akebia merged with Keryx Biopharmaceuticals under the former company's name.

Funding

Series A

On July 28, 2009 Akebia Therapeutics completed their series A funding round with $25 million in funding from Venture Investors (lead investor), Novartis Venture Fund (lead investor), Triathlon Medical Venture Partners, Orchard Venture Partners, Kearny Venture Partners, and Athenian Venture Partners.

Series B

On April 26, 2011 Akebia Therapeutics completed their series B funding round with $22 million in funding from Venture Investors (lead investor), Novartis Venture Fund (lead investor), Triathlon Medical Venture Partners, Orchard Venture Partners, Kearny Venture Partners, and Athenian Venture Partners, and AgeChem Venture Partners.

Series C

On June 4, 2013 Akebia Therapeutics completed their series C funding round with $41 million in funding from Satter Investment Management (lead investor), Nova Holdings (lead investor), Venture Investors, Triathlon Medical Venture Partners, Orchard Venture Partners, Novo Holdings, Novartis Venture Fund, Kearny Venture Partners, Athenian Venture Partners, and AgeChem Venture Fund.

Timeline

December 2018

Merger with Keryx Biopharmaceuticals

In December 2018, Akebia merged with Keryx Biopharmaceuticals under the former company's name.

June 4, 2013

Series C funding round

On June 4, 2013 Akebia Therapeutics completed their series C funding round with $41 million in funding from Satter Investment Management (lead investor), Nova Holdings (lead investor), Venture Investors, Triathlon Medical Venture Partners, Orchard Venture Partners, Novo Holdings, Novartis Venture Fund, Kearny Venture Partners, Athenian Venture Partners, and AgeChem Venture Fund.

April 26, 2011

Series B funding round

On April 26, 2011 Akebia Therapeutics completed their series B funding round with $22 million in funding from Venture Investors (lead investor), Novartis Venture Fund (lead investor), Triathlon Medical Venture Partners, Orchard Venture Partners, Kearny Venture Partners, and Athenian Venture Partners, and AgeChem Venture Partners.

July 8, 2009

Series A funding round

On July 28, 2009 Akebia Therapeutics completed their series A funding round with $25 million in funding from Venture Investors (lead investor), Novartis Venture Fund (lead investor), Triathlon Medical Venture Partners, Orchard Venture Partners, Kearny Venture Partners, and Athenian Venture Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Akebia Therapeutics Series C round
41,000,000
June 4, 2013
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Brittany Recker

Employee

Jason Amello

Senior VP & CFO

John Butler

President & CEO

Julia Moore

Investor

Karen Tubridy

Senior VP & Chief Development Officer

Kendra Miller

Employee

Mario Nelson

Employee

Michael Dahan

Senior VP & Chief Business Officer

Mike Venerable

Investor

Nikki Hadas

Senior VP & General Counsel

Rita Jain

Senior VP & Chief Medical Officer

Steve Turnbull

Investor

Tamara Dillon

Senior VP of Human Resources

Todd Kenney

Employee

Further reading

Title
Author
Link
Type
Date

Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease

Business Wire

Web

Akebia Therapeutics Shareholders Approve Merger with Keryx

BusinessWire

Web

Akebia: Is This A Potential Winner?

BioSci Capital Partners

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 18, 2020
BioSpace
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500TM , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tec
American Kidney Fund
Invalid Date
www.prnewswire.com:443
ROCKVILLE, Md., Feb. 13, 2019 /PRNewswire/ -- The American Kidney Fund is marking the 30th year of its Clinical Scientist in Nephrology Program in 2019 with...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.